Compare Cassava Sciences Inc (FLNA) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PubMatic Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while PubMatic Inc trades at $18.64 (market cap $850.88M). The key difference: PubMatic Inc is far larger — about 21.6× Cassava Sciences Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and PubMatic Inc for 40 Days on average.
| FLNA | PUBM | |
|---|---|---|
Market Cap | $39.40M | $850.88M |
Volume | 759,018 | 997,698 |
Sector | Health | Technology |
52-Week High | $4.64 | $19.18 |
52-Week Low | $0.68 | $6.28 |
Typical Hold Time | 37 Days | 40 Days |
Enterprise Value | -$43.28M | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
PubMatic (PUBM) trades at $18.68, up 0.59% with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with revenue growth of 11% year-over-year and an EPS beat, though profitability remains challenged with negative net margins. Recent leadership appointments and AI product developments signal strategic focus on growth. Analyst consensus is bullish with 11 buy ratings and a $19.89 price target, representing 6.5% upside potential.
The stock presents a growth opportunity in digital advertising technology with AI-driven products gaining traction, but faces execution risks amid negative profitability and competitive pressures. Revenue growth acceleration and margin improvement will be critical for sustained upside, while current valuation multiples remain elevated relative to earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
